After a general presentation of the Horizon Europe FP9 programme, the 2021 EURASC Symposium will be dedicated to the increasing roles of micro- and nanotechnologies for medicine and life sciences. This event is co-organized by the Foundation for rare Diseases and will be on line.
This will be illustrated by many examples: nanoparticles for drug delivery and as a tool to escape multidrug resistance in cancer, nano-sized recombinant viruses for gene therapy, nano-engines such as the CRSPR-Cas9 complex which is in the way to revolutionize precision medicine by allowing precise genome editing.
In addition, micrometer sized cells, which have been genetically modified by using nanometric recombinant viruses, have proved successful for numerous rare disorders, such as those of the immune system, or beta-thalassemia. Such gene/cell therapies represent also one of the most exciting recent breakthroughs in cancer.
Strikingly, the very same nanolipid particles which had been originally developed to treat rare disease by using oligonucleotides or RNA-interfering genetic drugs, have been successfully used for the recent mRNA vaccines against COVID-19 and other viruses.
Prestigious invited speakers will describe these dramatic advances and will also detail how mathematical epidemiological models can be implemented for the control of the COVID-19 pandemic. In the final presentation, ethical considerations for biomedicine will be presented and discussed.
For more informations and register : https://evenements-fondation-maladiesrares.org/event/2021-eurasc-symposium/